Sanofi is strengthening its R&D strategy with the €3.9 billion acquisition of Ablynx, a biopharma outfit specialising in the discovery and development on Nanobodies.
“With Ablynx, we continue to advance the strategic transformation of our Research and Development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders,” said Sanofi CEO Olivier Brandicourt.
Ablynx’s CEO Edwin Moses added: “Since our founding in 2001, our team has been focused on unlocking the power of our Nanobody technology for patients. The results of our work are validated by clinical data.
“As we look ahead, we believe Sanofi’s global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline.”
Sanofi said the acquisition continues its “commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules”.
Nanobodies are a novel class of proprietary next generation biologicals. Ablynx is at the leading edge of Nanobody technology supporting a deep pipeline of more than 45 proprietary and partnered candidates for a wide range of therapeutic areas such as haematology, inflammation, immuno-oncology and respiratory diseases. Eight Nanobodies have entered clinical development.
Ablynx’s most-advanced product in development is caplacizumab (anti-vWF Nanobody), a wholly-owned development program for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
The product is already filed in the European Union and expected to be filed in the U.S. during the first half of this year. Caplacizumab, if approved, would be the first-in-class treatment for this acute, life-threatening disease.
The addition of caplacizumab to Sanofi’s platform strengthens its position in rare blood disorders, complementing the recently announced agreements to acquire Bioverativ and obtain global rights for fitusiran from Alnylam.